Medexus Pharmaceuticals (TSE:MDP) Reaches New 52-Week High on Analyst Upgrade

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price hit a new 52-week high during trading on Wednesday after Stifel Nicolaus raised their price target on the stock from C$4.15 to C$4.50. The company traded as high as C$4.60 and last traded at C$4.52, with a volume of 77011 shares. The stock had previously closed at C$4.47.

A number of other brokerages also recently weighed in on MDP. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Two analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Price Performance

The stock has a market cap of C$108.42 million, a PE ratio of 88.40 and a beta of 1.96. The company’s fifty day moving average is C$2.88 and its 200-day moving average is C$2.59.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.